Kowa Company Limited

Yuichiro Tabunoki

Masahiro Tamura

Tetsuya Ishikawa

Seiichi Sato

Hajime Yamada

Hiroyuki Ishiwata

Takahiro Kitamura

Takeshi Doi

Shunji Takemura

Manabu Shibasaki

Yoshiharu Miyake

Masanori Ashikawa

Takatoshi Ozawa

Hideyuki Kobayashi

Akiyasu Kouketsu

Ryota Shigemi

Yukihiko Saeki

To provide a novel JAK3 inhibitor that is useful as a preventive and/or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sj&#xf6;gren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): or its salt or a solvate thereof.

Pyridine-3-carboxyamide derivative

The present invention provides a preventive or therapeutic drug for a myeloma tumor and osteoclastic bone loss associating therewith, the drug containing as an active ingredient an osteopontin-production regulator or inhibitor; a screening method for a preventive or therapeutic drug for a myeloma tumor, characterized by determining osteopontin production regulatory or inhibitory effect; as well as a diagnostic kit for a myeloma tumor, characterized by including a reagent for measuring blood osteopontin level, and a diagnostic method.

Preventives/remedies for myeloma tumor and method of diagnosing the same

Growing community of inventors

Higashimurayama, Japan

Yuichiro Tabunoki